Article
Evaluation of the effectiveness of ChondroFiller® liquid for the treatment of severe cartilage damage (grade III–IV) in the knee joint
Search Medline for
Authors
-
Cornelia Mardare
- meidrix biomedicals GmbH, Esslingen, Germany
-
Saskia Rödel
- St. Augustinus Gruppe, Johanna Etienne Krankenhaus, Neues, Germany
-
Patrick Joseph
- Clinic for Orthopaedics, Johanna Etienne Hospital, Neues, Germany
-
Ulrich Schneider
- iRegMed, Gmund am Tegernsee, Germany
-
Michaela Noll
- meidrix biomedicals GmbH, Esslingen, Germany
| Published: | October 21, 2024 |
|---|
Outline
Text
Objectives: ChondroFiller® liquid is a biological, acellular matrix that has been developed to stimulate cartilage regeneration in joints. The type I collagen matrix of ChondroFiller® liquid provides a scaffold for the migration of chondrocytes and stem cells and the regeneration of innate healthy collagen type II. This post-marketing study aimed to examine the effectiveness and safety of the CE-certified ChondroFiller® liquid in patients with severe grade III–IV cartilage damage.
Methods: The study was conducted as a retrospective study with 68 patients age 51.65±15.14, and a BMI of 28.31±4.85. Most of the patients were diagnosed with osteoarthritis and sports injuries. Treated defects were in the medial femoral condyle (48.86%), trochlea femoris (23.86%), and retropatellar (19.32%). The follow-ups were at 6 (n=68), 12 (n=35), and 36 months (n=22). The IKDC scores, MOCART score, and the number of patients with bone marrow edema were evaluated as well as patients’ satisfaction with the procedure and adverse effects. The data were analyzed by two-way ANOVA.
Results and conclusion: ChondroFiller® liquid improved significantly (p<0.0001) the IKDC score and IKDC subscale scores for symptoms, function, and activity in patients with cartilage damage grade III–IV of the knee joint. The improvement occurred in the first 6 months and remained at this high level for the following years. The MOCART score was at >83 points 12 months post-treatment. No adverse effects were reported after treatment with ChondroFiller® liquid. Bone marrow edema improved 12 months post-treatment in 63.64% of patients (n=46).
ChondroFiller® liquid significantly improved mobility and quality of life and increased ability to exercise which results in better overall health for patients with severe cartilage damage. The therapy with ChondroFiller® liquid results in complete defect filling through the collagen implant, which provides the chondrocytes with a matrix framework for cell migration and regeneration into articular cartilage tissue, accompanied by a significant reduction in pain due to covering of the exposed subchondral underlying bone and reduction of bone edema. ChondroFiller® liquid did not show any adverse effects and is recommended by 96.67% of patients (n=30).
